Screener
Insight Molecular Diagnostics Inc. IMDX Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 48.3%-6.9pp | 50.7%-3.6pp | 56.7%+12.7pp | 55%— | 55.3%— | |
| Operating margin | -3,011.9%-1,514pp | -2,500.7%-977pp | -1,260.8%+1,984pp | -1,392.9%+4,756pp | -1,498.3%+2,079pp | |
| Net margin | -2,955.6%-1,466pp | -2,454.6%-940pp | -1,238.5%+1,987pp | -1,380.7%+4,704pp | -1,489.7%+2,043pp | |
| Efficiency | ||||||
| Asset turnover | 0×0.0× | 0×0.0× | 0.1×+0.1× | 0.1×+0.1× | 0.1×+0.1× | |
| Liquidity | ||||||
| Current ratio | 2×-2.0× | 2.5×-1.2× | 1.3×-0.3× | 2.8×+2.3× | 4×+2.7× | |
| Per Share | ||||||
| Book value per share | -$0.58-1,790% | -$0.31-178% | -$1.03-9.9% | -$0.29-141% | $0.03-98.1% | |
| Valuation | ||||||
| Market capitalization | $107.34M-1.3% | $105.51M— | $214.98M— | $95.02M— | $98.67M— | |
| Price / sales | 64.3×+39.6× | 54.1×— | 53×— | 21.6×— | 23.2×— |
FAQ
- What are Insight Molecular Diagnostics Inc.'s profit margins?
- Insight Molecular Diagnostics Inc. (IMDX) runs a 48.3% gross margin and a -3011.9% operating margin, with a -2955.6% net margin.
- Where do Insight Molecular Diagnostics Inc.'s ratios come from?
- Every ratio is computed from Insight Molecular Diagnostics Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
